Genomic profiling partnerships KEW specializes in comprehensive genomic profiling for cancer care and is actively partnering with molecular labs to expand adoption of CANCERPLEX. This indicates a clear sales path in B2B collaborations with lab networks seeking to enhance precision medicine offerings for local practice.

Clinical product focus CANCERPLEX is KEW's flagship solution for identifying genetic variants and matching them to targeted therapies in solid tumors.Sales opportunities exist in expanding access to this core product within community hospitals and independent clinics that want validated genomic profiling to guide treatments.

Growth potential With a mid-size team (11-50 employees) and revenue in the tens of millions, KEW demonstrates scalable operations and readiness for broader deployment. Target opportunities may include strategic partnerships, channel distributors, and joint marketing with established lab networks to accelerate adoption.

Funding readiness KEW has raised substantial funding ($33M), signaling financial capacity to scale partnerships, invest in deployment of CANCERPLEX across additional labs, and support pilot programs with healthcare systems seeking genomic-driven care.

Geographic/academic heritage Headquartered in Cambridge, MA, KEW has ties to prominent precision medicine pioneers and collaborations with major players (e.g., Invitae). This positioning can be leveraged to pursue enterprise customers in academic medical centers and regional networks seeking trusted, research-backed genomic solutions.